Drug Trial Radar · NCT05118919
A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Jun 26, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
35
Actual
Start
Feb 9, 2022
Primary completion
Dec 31, 2024
Study completion Dec 31, 2024
Sponsor
- Lead sponsor
- BioGaia Pharma ABIndustry
- Sponsor type
- Industry
- First posted
- Nov 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the safety, tolerability and preliminary efficacy of Lactobacillus reuteri BGP-014 in mild to moderate active Ulcerative Colitis (UC) patients as an oral administered local treatment in addition to Standard of Care (SoC) treatment.
Conditions
- Ulcerative Colitis
Interventions
BGP-014Biological
Oral capsule containing lyophilised Lactobacillus reuteri
PlaceboBiological
Oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of adverse eventsTime frame: Up to 10 weeks
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Department of Gastroenterology and Hepatology, Linköping University Hospital
Linköping, Sweden
Gastroenterology Department, Danderyds Hospital
Stockholm, Sweden
Gastroenterology Department, Ersta Hospital
Stockholm, Sweden
Department of Medical Sciences Gastroenterology and Hepatology, Uppsala University Hospital
Uppsala, Sweden
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.